Manfred P. Wirth
YOU?
Author Swipe
View article: A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer
A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer Open
Background Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognosti…
View article: Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be? Open
As there are more prostate cancer survivors than ever before, research into cancer survivorship is crucial. We highlight the importance of such research and provide recommendations on how to carry it out. The first step should be establish…
View article: Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass) Open
Patients with metastatic kidney cancer who experienced a tumor response or disease stabilization after a short period of targeted treatment with a tyrosine kinase inhibitor did not benefit from a switch to the immunotherapy drug nivolumab.…
View article: Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer
Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer Open
Background Prostate cancer (PCa) is one of the most prevalent cancers worldwide. The clinical manifestations and molecular characteristics of PCa are highly variable. Aggressive types require radical treatment, whereas indolent ones may be…
View article: A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program
A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program Open
View article: Supplementary Table S5 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S5 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes involved in WNT signaling pathway in the ALDH+ population of DU145 radioresistant (RR) cells versus ALDH- population of DU145 RR cells.
View article: Supplementary Table S2 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S2 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Gene set enrichment analysis (GSEA) for DU145 radioresistant (RR) cells versus DU145 parental (P) cells, NOM p value < 0.05.
View article: Supplementary Table and Figure Legend from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table and Figure Legend from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Legend for Supplementary Tables S1-S5 and Supplementary Figures S1-S10.
View article: Supplementary Table S3 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S3 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes involved in WNT signaling pathway in the entire population of DU145 parental (P) cells versus DU145 radioresistant (RR) cells.
View article: Data from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Data from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Radiotherapy is a mainstay of curative prostate cancer treatment, but risks of recurrence after treatment remain significant in locally advanced disease. Given that tumor relapse can be attributed to a population of cancer stem cells (CSC)…
View article: Supplementary Table S1 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S1 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes that were not mapped within the deleted or amplified chromosomal regions in the entire population of DU145 parental (P) cells versus DU145 radioresistant (RR) cells.
View article: Supplementary Table S3 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S3 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes involved in WNT signaling pathway in the entire population of DU145 parental (P) cells versus DU145 radioresistant (RR) cells.
View article: Supplementary Methods and Reference from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Methods and Reference from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Description of additional methods and procedures used in the study. Also includes Supplementary Reference.
View article: Data from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Data from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Radiotherapy is a mainstay of curative prostate cancer treatment, but risks of recurrence after treatment remain significant in locally advanced disease. Given that tumor relapse can be attributed to a population of cancer stem cells (CSC)…
View article: Supplementary Figures S1-S10 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Figures S1-S10 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Irradiation-induced changes in the expression of stem cell markers (S1); Genetic alterations in the irradiated prostate cancer cells (S2); Regulation of histone methylation in response to cell irradiation (S3); Differential expression of s…
View article: Supplementary Table S1 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S1 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes that were not mapped within the deleted or amplified chromosomal regions in the entire population of DU145 parental (P) cells versus DU145 radioresistant (RR) cells.
View article: Supplementary Table S5 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S5 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes involved in WNT signaling pathway in the ALDH+ population of DU145 radioresistant (RR) cells versus ALDH- population of DU145 RR cells.
View article: Supplementary Table S2 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S2 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Gene set enrichment analysis (GSEA) for DU145 radioresistant (RR) cells versus DU145 parental (P) cells, NOM p value < 0.05.
View article: Supplementary Table S4 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S4 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes involved in WNT signaling pathway in the ALDH+ population of DU145 parental (P) cells versus ALDH- population of DU145 P cells.
View article: Supplementary Table S4 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table S4 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Regulation of the genes involved in WNT signaling pathway in the ALDH+ population of DU145 parental (P) cells versus ALDH- population of DU145 P cells.
View article: Supplementary Figures S1-S10 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Figures S1-S10 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Irradiation-induced changes in the expression of stem cell markers (S1); Genetic alterations in the irradiated prostate cancer cells (S2); Regulation of histone methylation in response to cell irradiation (S3); Differential expression of s…
View article: Supplementary Table and Figure Legend from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Table and Figure Legend from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Legend for Supplementary Tables S1-S5 and Supplementary Figures S1-S10.
View article: Supplementary Methods and Reference from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Supplementary Methods and Reference from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells Open
Description of additional methods and procedures used in the study. Also includes Supplementary Reference.
View article: Supplementary Methods, Table 1, Figure S1-S9 from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells
Supplementary Methods, Table 1, Figure S1-S9 from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells Open
Supplementary Methods, Table 1, Figure S1-S9 (i) supplementary methods: Human tumor tissue dissociation, Immunofluorescence microscopy, Clonogenic cell survival assay, Sphere formation assay, Cell proliferation and cytotoxicity assay, Woun…
View article: Data from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells
Data from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells Open
Radiotherapy is a curative treatment option in prostate cancer. Nevertheless, patients with high-risk prostate cancer are prone to relapse. Identification of the predictive biomarkers and molecular mechanisms of radioresistance bears promi…
View article: Data from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells
Data from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells Open
Radiotherapy is a curative treatment option in prostate cancer. Nevertheless, patients with high-risk prostate cancer are prone to relapse. Identification of the predictive biomarkers and molecular mechanisms of radioresistance bears promi…
View article: Supplementary Methods, Table 1, Figure S1-S9 from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells
Supplementary Methods, Table 1, Figure S1-S9 from Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells Open
Supplementary Methods, Table 1, Figure S1-S9 (i) supplementary methods: Human tumor tissue dissociation, Immunofluorescence microscopy, Clonogenic cell survival assay, Sphere formation assay, Cell proliferation and cytotoxicity assay, Woun…
View article: Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)
Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P) Open
Progression of prostate-specific antigen (PSA) values after curative treatment of prostate cancer patients is common. Prostate-specific membrane antigen (PSMA-) PET imaging can identify patients with metachronous oligometastatic disease ev…
View article: Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography–staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial
Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography–staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial Open
Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research. We hypothesize that aRT is safe and effective in gallium-68 prostate-specific membrane antige…